Literature DB >> 9039591

Contrast-enhanced MR imaging in the evaluation of treatment response and prediction of outcome in multiple sclerosis.

J H Simon1.   

Abstract

MR imaging is becoming increasingly important in the evaluation of multiple sclerosis based on its sensitivity to acute, often subclinical events in the brain and because it provides a basis for measuring the accumulation of disease over time. Contrast-enhanced MR imaging in particular evaluates disease at the fundamental level of events affecting the blood-brain barrier. This review emphasizes (a) recent developments in the use of contrast-enhanced MR imaging as a measure of disease in patient groups and individuals and (b) its emerging role in evaluating new therapies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9039591     DOI: 10.1002/jmri.1880070106

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  8 in total

1.  Enhancing patterns in multiple sclerosis: evolution and persistence.

Authors:  J He; R I Grossman; Y Ge; L J Mannon
Journal:  AJNR Am J Neuroradiol       Date:  2001-04       Impact factor: 3.825

2.  Whole-brain atrophy in multiple sclerosis measured by automated versus semiautomated MR imaging segmentation.

Authors:  Jitendra Sharma; Michael P Sanfilipo; Ralph H B Benedict; Bianca Weinstock-Guttman; Frederick E Munschauer; Rohit Bakshi
Journal:  AJNR Am J Neuroradiol       Date:  2004 Jun-Jul       Impact factor: 3.825

3.  Focal neurologic deficit.

Authors:  F J Wippold
Journal:  AJNR Am J Neuroradiol       Date:  2008-11       Impact factor: 3.825

4.  Investigation of apparent diffusion coefficient and diffusion tensor anisotrophy in acute and chronic multiple sclerosis lesions.

Authors:  A L Tievsky; T Ptak; J Farkas
Journal:  AJNR Am J Neuroradiol       Date:  1999-09       Impact factor: 3.825

5.  Clinical Significance of Diffusion-weighted Magnetic Resonance Imaging on Treatment Efficacy in MS Patients With Acute Attacks.

Authors:  Faezeh Asaadi; Fariborz Faeghi; Farzad Ashrafi; Morteza Sanei Taheri
Journal:  Basic Clin Neurosci       Date:  2021-11-01

6.  Brain metabolite profiles of T1-hypointense lesions in relapsing-remitting multiple sclerosis.

Authors:  Belinda S Y Li; Juleiga Regal; Brian J Soher; Lois J Mannon; Robert I Grossman; Oded Gonen
Journal:  AJNR Am J Neuroradiol       Date:  2003-01       Impact factor: 3.825

7.  Zinc-ion binding and cytokine activity regulation pathways predicts outcome in relapsing-remitting multiple sclerosis.

Authors:  A Achiron; M Gurevich; Y Snir; E Segal; M Mandel
Journal:  Clin Exp Immunol       Date:  2007-05-04       Impact factor: 4.330

8.  Dose and Frequency of Administration of Interferon-beta Affect its Efficacy in Multiple Sclerosis.

Authors:  Mohammed K Sharief
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.